Abstract
Glioblastoma (GBM) is a highly aggressive and invasive tumor that confers high mortality rates and low survival. The standard treatment consists of surgical resection of the tumor, accompanied by radiotherapy and chemotherapy associated with the use of temozolomide (TMZ), a DNA alkylating agent that, administered to the patient, promotes a slight increase in survival. However, GBM present…